Feb-14-18 Downgrade
JP Morgan
Neutral → Underweight
Feb-02-18 Initiated
H.C. Wainwright
Buy
$10
Aug-09-16 Reiterated
FBR Capital
Mkt Perform
$9 → $8
Feb-23-16 Reiterated
FBR Capital
Mkt Perform
$14 → $10
Feb-23-16 Downgrade
Morgan Stanley
Equal-Weight → Underweight
Feb-23-16 Downgrade
Barclays
Overweight → Equal Weight
$12 → $6
Feb-22-16 Downgrade
Citigroup
Buy → Neutral
Dec-29-15 Downgrade
JP Morgan
Overweight → Neutral
$65 → $15
Dec-28-15 Reiterated
Piper Jaffray
Overweight
$63 → $10
Dec-28-15 Downgrade
FBR Capital
Outperform → Mkt Perform
$73 → $14
Dec-17-15 Initiated
UBS
Buy
$55
Oct-05-15 Downgrade
Morgan Stanley
Overweight → Equal-Weight
Sep-03-15 Initiated
Citigroup
Buy
Aug-18-15 Initiated
FBR Capital
Outperform
$73
Aug-06-15 Reiterated
Brean Capital
Buy
$50 → $57
May-11-15 Reiterated
Brean Capital
Buy
$45 → $50
Mar-04-15 Initiated
Barclays
Overweight
$55
Feb-12-15 Reiterated
Stifel
Buy
$47 → $57
Dec-31-14 Reiterated
Brean Capital
Buy
$33 → $45
Jul-08-14 Resumed
Brean Capital
Buy
$33
Jan-20-21 08:03PM
Jan-19-21 04:19PM
Jan-11-21 10:29AM
Jan-08-21 07:48PM
04:25PM
07:25AM
06:00AM
Jan-06-21 08:00AM
Dec-22-20 12:41AM
Dec-12-20 10:30PM
Dec-08-20 08:56AM
Dec-07-20 07:00AM
Nov-07-20 08:33AM
Nov-06-20 05:50AM
Nov-05-20 04:01PM
07:00AM
Oct-29-20 07:00AM
Oct-28-20 08:12AM
Sep-13-20 10:21AM
Sep-10-20 08:00AM
Aug-10-20 08:25AM
07:28AM
07:00AM
Aug-03-20 08:00AM
Jul-15-20 12:22PM
Jul-05-20 02:43PM
Jun-22-20 07:00AM
Jun-18-20 08:00AM
May-28-20 08:00AM
May-12-20 06:47AM
May-07-20 10:25AM
09:07AM
07:00AM
May-02-20 08:40AM
Apr-29-20 07:00AM
Apr-28-20 04:30PM
Mar-26-20 08:18AM Thomson Reuters StreetEvents +7.86%
Mar-18-20 06:26AM
Feb-28-20 12:00PM
Feb-26-20 08:00AM
Feb-25-20 07:00AM
06:30AM
Feb-24-20 08:00AM
Feb-18-20 08:00AM
Feb-06-20 07:04AM
Feb-05-20 11:52AM
Jan-29-20 08:00AM
Jan-03-20 11:30AM
Dec-23-19 06:12AM
Dec-16-19 01:04AM
Dec-14-19 08:59PM
Dec-10-19 07:30AM
Dec-04-19 01:01AM
Nov-22-19 12:02AM Thomson Reuters StreetEvents
Nov-07-19 06:19AM
Nov-05-19 07:00AM
Nov-04-19 04:01PM
Oct-29-19 08:00AM
Oct-02-19 08:47AM
Oct-01-19 08:10AM
Sep-30-19 07:30PM
Sep-27-19 08:00AM
Aug-27-19 01:13PM
Aug-08-19 09:35AM
08:00AM
Aug-07-19 10:30AM
Aug-05-19 07:55AM American City Business Journals -11.52%
Jul-31-19 07:00AM
Jul-12-19 03:07PM
Jun-28-19 06:41PM
May-17-19 08:18AM Thomson Reuters StreetEvents
May-16-19 09:11AM
May-09-19 09:25AM
08:25AM
08:00AM
06:30AM
May-02-19 04:01PM
Apr-29-19 10:31AM
Apr-12-19 01:43PM
Apr-09-19 11:21AM American City Business Journals +31.10%
08:10AM
Apr-08-19 05:00PM
Apr-05-19 02:14PM American City Business Journals
Mar-26-19 06:30PM Thomson Reuters StreetEvents +7.43%
Mar-07-19 12:24PM
Mar-05-19 07:00AM
Mar-04-19 08:00AM
Feb-26-19 08:00AM
Feb-22-19 08:00AM
Feb-14-19 08:15AM American City Business Journals -7.08%
Feb-11-19 07:55AM
Feb-06-19 02:20PM American City Business Journals
08:00AM
Jan-30-19 11:51AM
Jan-24-19 10:17AM
10:03AM
Jan-18-19 06:36AM
Jan-17-19 09:38AM
Jan-04-19 07:30AM
Dec-27-18 09:23AM American City Business Journals +6.52%
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
DEMSKI MARTHA J Director Nov 17 Option Exercise 2.35 7,042 16,549 7,042 Nov 19 12:57 PM Jakeman David Principal Accounting Officer Oct 02 Sale 2.48 4,270 10,590 85,117 Oct 02 04:06 PM Meyer Robert J. Director Aug 19 Buy 2.92 3,500 10,220 13,500 Aug 19 05:34 PM DEMSKI MARTHA J Director Aug 10 Option Exercise 3.16 1,584 5,005 1,584 Aug 11 05:49 PM DEMSKI MARTHA J Director Aug 10 Sale 3.25 1,584 5,148 0 Aug 11 05:49 PM DEMSKI MARTHA J Director Aug 07 Option Exercise 3.16 2,500 7,900 2,500 Aug 10 05:54 PM DEMSKI MARTHA J Director Aug 07 Sale 3.25 2,500 8,125 0 Aug 10 05:54 PM DEMSKI MARTHA J Director Aug 06 Option Exercise 3.16 2,500 7,900 2,500 Aug 10 05:54 PM DEMSKI MARTHA J Director Aug 06 Sale 3.29 2,500 8,224 0 Aug 10 05:54 PM DEMSKI MARTHA J Director Aug 05 Option Exercise 3.16 2,500 7,900 2,500 Aug 06 12:55 PM DEMSKI MARTHA J Director Aug 05 Sale 3.27 2,500 8,187 0 Aug 06 12:55 PM DEMSKI MARTHA J Director Aug 04 Option Exercise 3.16 5,000 15,800 5,000 Aug 06 12:55 PM DEMSKI MARTHA J Director Aug 04 Sale 3.25 5,000 16,250 0 Aug 06 12:55 PM Andriole Michael T. Chief Business Officer Mar 16 Buy 1.43 33,300 47,522 149,729 Mar 17 11:58 AM MIDDLETON FRED A Director Mar 12 Buy 1.40 50,000 69,900 197,523 Mar 16 12:19 PM Sherman Michael A. Chief Executive Officer Mar 12 Buy 1.45 72,995 105,653 102,995 Mar 16 12:51 PM Nichols Garrett Chief Medical Officer Feb 10 Sale 1.68 8,805 14,830 260,066 Feb 11 04:19 PM Nichols Garrett Chief Medical Officer Feb 07 Sale 1.70 2,550 4,335 268,871 Feb 11 04:19 PM Jakeman David Principal Accounting Officer Feb 07 Sale 1.70 2,290 3,893 87,876 Feb 11 04:16 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite